Sentences with word «sorafenib»

«Due to our prior successes in treating these patients with sorafenib and lenvatinib, patients are doing better, but they still ultimately progress, and we need additional agents with different mechanisms of action,» Brose said.

All in all, the researchers maintain that their results support the use of sorafenib in combination with other drugs in the treatment of multiple myeloma.

«Researchers reported a response rate of 19 percent, which is much better than the 2 percent response rate with the FDA - approved drug sorafenib (Nexavar),» Chung said.

iCAGES used the genomic sequencing data to select sorafenib as the top drug candidate out of 122 possible treatments.

«The patient was given sorafenib and had an extraordinary clinical response,» said Dr. Wang.

Notwithstanding the survival advantage offered by sorafenib, a great margin of improvement may be envisaged particularly for nonresponders, as well as for those patients who experience escape from treatment efficacy.

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.

Because sorafenib inhibits the chemical signals that can trigger both cellular proliferation and new blood vessel growth, Gomberg - Maitland and colleagues suspected it might slow the growth and thickening of the pulmonary artery walls.

She has had no other complications and her persistent rash from the prostacylin went away after two weeks on sorafenib.

sorafenib induces cell death in human myeloma cell lines in a laboratory environment by preventing a certain kind of protein - level activity, an effect that also was achieved when the myeloma cells had developed a resistance to

Researchers enrolled 573 patients with intermediate or advanced stage hepatocellular carcinoma, who had all been previously treated with sorafenib, and randomized them 2:1 to 160 mg oral regorafenib or placebo once daily for 1 - 3 of each four week cycle, in addition to best supportive care.

• Subject has received prior treatment with ASP2215 or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first - line therapy regimen as part of induction, consolidation, and / or maintenance).

The Freiburg team demonstrated that the drugs sorafenib and axitinib, which are currently approved only for kidney and liver cancer, are effective in CML model systems as well.

The scientists tested neratinib in animal models of breast cancer and found that it enhanced the effectiveness of previously established drug combinations, including pemetrexed and sorafenib, which is currently being tested in a phase 2 clinical trial at Massey for the treatment of triple negative breast cancer.

The analysis suggests that patients with complex indels in KIT would benefit from drugs such as imatinib, sunitnib and sorafenib, which target mutations in this gene.

Dent is collaborating with Massey clinical researchers to propose a study investigating the effectiveness of the combination of neratinib, sorafenib and pemetrexed in all advanced solid tumors.

Vemurafenib joins other multi-targeted kinase inhibitors (MKIs)(sorafenib, lenvatinib) shown to be effective in this patient population; in spite of responses to these drugs, the responses are temporary and additional treatment options are needed.

«It's worth noting that sorafenib is not FDA - approved for this indication.

Regorafenib had a similar safety and side effect profile to sorafenib, with hypertension, hand - foot skin reaction, fatigue and diarrhea all being significantly more common in patients taking the drug.

«Systemic treatment for hepatocellular carcinoma has long consisted of just one agent — sorafenib - which was shown to provide a significant improvement in life expectancy almost 10 years ago, but no other agent has surpassed its benefits,» said the study's principal investigator Dr Jordi Bruix, Head of the BCLC group at the Hospital Clínic and Scientific Director of the Network for Biomedical Research for Hepatic and Digestive Diseases (CIBEREHD).

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

The advent of sorafenib has shown that molecularly targeted agents can effectively impact survival in patients with HCC and their side effects can be managed even in patients with cirrhosis.

But, those that received sorafenib or sorafenib plus S5416, had negligible pressure increases.

[68] Other KIT inhibitors, such as sorafenib, dasatinib, and sunitinib, have also been reported to have beneficial effects in mucosal melanomas harboring KIT mutations.

Rats in the reduced - oxygen chambers received: no medication, a drug called SU5416 (well known to cause severe pulmonary hypertension in this setting), SU5416 plus sorafenib, or sorafenib alone.

Although originally designed to fight colon cancer, the drug, sorafenib (Nexavar ®), proved much more effective against kidney cancer.

To test this theory they treated rats at high risk for pulmonary hypertension with sorafenib.

For patients with advanced liver cancer, nivolumab (Opdivo ®), an anti-PD-1 checkpoint inhibitor, has been approved for those previously treated with sorafenib.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Gomberg - Maitland — who is married to a member of the sorafenib - cancer team — recognized with her husband that its effects also might slow the growth and thickening of the pulmonary artery walls.